• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

质子泵抑制剂停药临床指南

The Clinician's Guide to Proton-Pump Inhibitor Discontinuation.

机构信息

Department of Internal Medicine, Rady School of Medicine, University of Manitoba, Winnipeg, MB, Canada.

出版信息

J Clin Gastroenterol. 2019 Sep;53(8):553-559. doi: 10.1097/MCG.0000000000001243.

DOI:10.1097/MCG.0000000000001243
PMID:31356559
Abstract

There is increasing concern among patients and health care providers about the associations between PPI use and a multitude of potential adverse outcomes. Therefore, clinicians need to have a rational approach both to identifying PPI users who may not have an ongoing indication for their use and on how to encourage discontinuation of unnecessary PPI use. In this paper, we will provide a detailed review of the specific indications where the benefits of ongoing PPI use is of questionable value and will review the evidence on how to maximize the likelihood of being able to successfully discontinue PPI use while minimizing symptom recurrence.

摘要

越来越多的患者和医疗保健提供者对质子泵抑制剂 (PPI) 使用与多种潜在不良后果之间的关联表示担忧。因此,临床医生需要采取合理的方法,既要识别出那些可能不再需要继续使用 PPI 的患者,也要确定如何鼓励他们停止不必要的 PPI 使用。在本文中,我们将详细回顾那些持续使用 PPI 获益值得怀疑的具体适应证,并回顾有关如何最大限度地提高成功停用 PPI 的可能性,同时最大限度地减少症状复发的证据。

相似文献

1
The Clinician's Guide to Proton-Pump Inhibitor Discontinuation.质子泵抑制剂停药临床指南
J Clin Gastroenterol. 2019 Sep;53(8):553-559. doi: 10.1097/MCG.0000000000001243.
2
Patients' Perceptions of Proton Pump Inhibitor Risks and Attempts at Discontinuation: A National Survey.患者对质子泵抑制剂风险的认知及停药尝试:一项全国性调查。
Am J Gastroenterol. 2019 Feb;114(2):244-249. doi: 10.14309/ajg.0000000000000061.
3
A questionnaire on prescription patterns of proton pump inhibitors for hemodialysis patients in Japan.日本血液透析患者质子泵抑制剂处方模式调查问卷。
Clin Exp Nephrol. 2020 Jun;24(6):565-572. doi: 10.1007/s10157-020-01866-z. Epub 2020 Mar 8.
4
Do recent reports about the adverse effects of proton pump inhibitors change providers' prescription practice?近期有关质子泵抑制剂不良反应的报道是否改变了医疗服务提供者的处方习惯?
Dis Esophagus. 2018 Dec 1;31(12). doi: 10.1093/dote/doy042.
5
We have had a gutful: The need for deprescribing proton pump inhibitors.我们受够了:减少质子泵抑制剂处方的必要性。
J Clin Pharm Ther. 2018 Feb;43(1):65-72. doi: 10.1111/jcpt.12613. Epub 2017 Sep 11.
6
The Use and Misuse of Proton Pump Inhibitors: An Opportunity for Deprescribing.质子泵抑制剂的使用与误用:撤药的机会。
J Am Med Dir Assoc. 2021 Jan;22(1):15-22. doi: 10.1016/j.jamda.2020.09.046. Epub 2020 Dec 13.
7
AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.AGA 临床实践更新:质子泵抑制剂的撤药——专家综述。
Gastroenterology. 2022 Apr;162(4):1334-1342. doi: 10.1053/j.gastro.2021.12.247. Epub 2022 Feb 17.
8
Risk awareness for proton pump inhibition: Necessitates review of recommendations in anti-reflux disease.质子泵抑制的风险意识:有必要重新审视抗反流疾病的相关建议。
Surgeon. 2020 Jun;18(3):189-190. doi: 10.1016/j.surge.2019.09.001. Epub 2019 Oct 11.
9
Physicians' Perceptions of Proton Pump Inhibitor Risks and Recommendations to Discontinue: A National Survey.医生对质子泵抑制剂风险的认知及停药建议:一项全国性调查。
Am J Gastroenterol. 2020 May;115(5):689-696. doi: 10.14309/ajg.0000000000000558.
10
Successful deprescribing of unnecessary proton pump inhibitors in a primary care clinic.在基层医疗诊所成功停用不必要的质子泵抑制剂。
J Am Pharm Assoc (2003). 2020 Jan-Feb;60(1):100-104. doi: 10.1016/j.japh.2019.08.012. Epub 2019 Oct 7.

引用本文的文献

1
SAGES guidelines for the surgical treatment of gastroesophageal reflux (GERD).SAGES 指南:胃食管反流(GERD)的手术治疗。
Surg Endosc. 2021 Sep;35(9):4903-4917. doi: 10.1007/s00464-021-08625-5. Epub 2021 Jul 19.
2
Proton Pump Inhibitors and Incident Clostridioides difficile Infection: Beyond Controversy, Pragmatic Approaches Are Needed.质子泵抑制剂与艰难梭菌感染:超越争议,需要务实的方法。
Clin Infect Dis. 2021 Jun 15;72(12):e1090-e1092. doi: 10.1093/cid/ciaa1856.